ACADIA Pharmaceuticals (FRA:DR6) Research & Development: €281.3 Mil (TTM As of Mar. 2026)


FRA:DR6 ACADIA Pharmaceuticals Inc FRA:DR6
76 GF Score
Price €20.55
GF Value €21.67
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Research & Development?

ACADIA Pharmaceuticals FRA:DR6 +3.92% 76 Research & Development is €281.3 Mil as of Mar. 2026. GuruFocus rates FRA:DR6 with a GF Score™ of 76/100 and a GF Value™ of €21.67 (Fairly Valued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ACADIA Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was €66.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €281.3 Mil.

ACADIA Pharmaceuticals  (FRA:DR6) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ACADIA Pharmaceuticals Research & Development Related Terms

ACADIA Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Research & Development Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 211.88 341.33 322.44 289.60 280.80

ACADIA Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 72.40 67.58 74.83 72.38 66.49
FRA:DR6
76GF Score
ACADIA Pharmaceuticals Inc FRA:DR6
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €281.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €281.3 Mil mean?
ACADIA Pharmaceuticals (FRA:DR6) has a Research & Development of €281.3 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Research & Development too high?
ACADIA Pharmaceuticals' current Research & Development is €281.3 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Research & Development compare to EWTX and CRNX?
ACADIA Pharmaceuticals' Research & Development of €281.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Research & Development is €281.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (FRA:DR6) is currently considered Fairly Valued. The stock's GF Value™ is €21.67, compared to a current price of €20.55 — trading 5.2% below its estimated fair value. The current Research & Development is €281.3 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 76/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ACADIA Pharmaceuticals (FRA:DR6), the current Research & Development is €281.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (FRA:DR6) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be undervalued. The current stock price of €20.55 is trading 5.2% below its estimated GF Value™ of €21.67. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for FRA:DR6:

  • Research & Development: €281.3 Mil
  • GF Value™: €21.67 vs. price of €20.55 (5.2% below fair value)
  • GF Score™: 76/100 with 8 warning signs

No single metric tells the full story. See the FRA:DR6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USAACAD:Mexico
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
76GF Score

Get the complete analysis for FRA:DR6

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.55
Price
€21.67
GF Value